AstraZeneca, Isis Pharmaceuticals announce strategic collaboration
Tuesday, August 04, 2015
AstraZeneca and Isis Pharmaceuticals to discover and develop antisense drugs for cardiovascular, metabolic and renal diseases.
AstraZeneca will pay an upfront fee of $65 million to Isis Pharmaceuticals.
Isis Pharmaceuticals is also eligible to earn tiered double-digit royalties on annual net sales for each programme.
reuters.com
